Exozymes Inc.'s co-founder and VP of Research, Dr. Tyler Korman, recently discussed the company's unique approach to leveraging AI in enzyme development. Dr. Korman emphasized the critical role of proprietary enzyme data generation in optimizing exozymes for cell-free environments. By harnessing AI and large language models, Exozymes can rapidly design, build, and test more functional enzymes tailored for biomanufacturing and biocatalysis applications. He highlighted the company's "secret power" as its ability to directly measure enzyme functions, providing essential data to refine AI models and accelerate innovation in creating new molecules for pharmaceuticals, nutraceuticals, and specialty chemicals. No URL for the full speech or interview was provided in the document.